CN102258623B - Chinese medicine composition for treating coronary disease and cardiac insufficiency and preparation method thereof - Google Patents
Chinese medicine composition for treating coronary disease and cardiac insufficiency and preparation method thereof Download PDFInfo
- Publication number
- CN102258623B CN102258623B CN201010184304.XA CN201010184304A CN102258623B CN 102258623 B CN102258623 B CN 102258623B CN 201010184304 A CN201010184304 A CN 201010184304A CN 102258623 B CN102258623 B CN 102258623B
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- weight portions
- medicine composition
- cardiac insufficiency
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 208000029078 coronary artery disease Diseases 0.000 title abstract description 4
- 239000009636 Huang Qi Substances 0.000 claims abstract description 11
- 241000628997 Flos Species 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 9
- -1 alkaloid compound Chemical class 0.000 description 6
- 230000004217 heart function Effects 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000005541 ACE inhibitor Substances 0.000 description 3
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 3
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000036454 renin-angiotensin system Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- LAWPHHZXTUPSDG-UHFFFAOYSA-N Astragaloside I Natural products CC(=O)OC1C(O)COC(OC2CCC34CC35CCC6(C)C(C)(CCC6(O)C7(C)CCC(O7)C(C)(C)O)C5CC(OC8OC(CO)C(O)C(O)C8O)C4C2(C)C)C1OC(=O)C LAWPHHZXTUPSDG-UHFFFAOYSA-N 0.000 description 1
- KXHCYYSIAXMSPA-UHFFFAOYSA-N Astragaloside-I Chemical compound CC(=O)OC1C(OC(=O)C)C(O)COC1OC1C(C)(C)C2C(OC3C(C(O)C(O)C(CO)O3)O)CC3C4(C)CC(O)C(C5(C)OC(CC5)C(C)(C)O)C4(C)CCC43CC42CC1 KXHCYYSIAXMSPA-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 229940097420 Diuretic Drugs 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- DPMGVDIWDTYPMP-UHFFFAOYSA-N Hypaconitine Natural products COCC12CCC(OC)C3(CN(C)C1)C4CC5(O)C(OC)C(O)C(CC(OC)C23)(OC(=O)C)C4C5OC(=O)c6ccccc6 DPMGVDIWDTYPMP-UHFFFAOYSA-N 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 1
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000037369 collagen remodeling Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- HJCCJZGOBHFQSX-UHFFFAOYSA-N cyclosieversioside B Natural products CC(CCC(O)C(C)(C)OC1OC(CO)C(O)C(O)C1O)C2C(CC3(C)C4CC(O)C5C(C)(C)C(CCC56CC46CCC23C)OC7OCC(O)C(O)C7O)OC8OC(CO)C(O)C(O)C8O HJCCJZGOBHFQSX-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- FIDOCHXHMJHKRW-GKVQVCCJSA-N hypaconitine Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@]45[C@@H](OC)CC[C@@]6([C@H]4[C@@H](OC)[C@H]([C@@](OC(C)=O)([C@H]31)[C@@H](O)[C@H]2OC)[C@H]5N(C)C6)COC)C(=O)C1=CC=CC=C1 FIDOCHXHMJHKRW-GKVQVCCJSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- XUHJBXVYNBQQBD-UHFFFAOYSA-N mesaconitine Natural products COC1CC(O)C2(COC)CN(C)C3C(C(C45)(OC(C)=O)C(O)C6OC)C(OC)C2C31C4CC6(O)C5OC(=O)C1=CC=CC=C1 XUHJBXVYNBQQBD-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XUHJBXVYNBQQBD-GQPWXMLZSA-N molport-002-525-145 Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@]45[C@@H]6[C@@H](OC)[C@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H]4N(C)C[C@@]6([C@@H](C[C@@H]5OC)O)COC)C(=O)C1=CC=CC=C1 XUHJBXVYNBQQBD-GQPWXMLZSA-N 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 229930183842 salvianolic acid Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008700 sympathetic activation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a Chinese medicine composition for treating coronary disease and cardiac insufficiency and a preparation method thereof. The invention provides a Chinese medicine composition for treating chronic heart failure and a preparation method thereof. The composition comprises 10-30 weight portions of radix astragali, 10-20 weight portions of salvia miltiorrhiza, 5-15 weight portions of monkshood, 10-15 weight portions of radix scrophulariae, 10-20 weight portions of honeysuckle flower and 5-15 weight portions of licorice, and prepared by extracting the effective ingredients of the formula with a certain preparation technology, then mixing the ingredients according to the dosages and preparing into the granular formulation. A patient needs to take one packet of the Chinese medicine composition two times per day.
Description
Technical field
The present invention relates to Traditional Chinese medicine composition field, be specially a kind of pharmaceutical composition that heart function of coronary heart disease is incomplete that is used for the treatment of, is the active component Chinese medicine with QI invigorating warming YANG, promoting blood circulation and detoxication effect.
Background technology
Cardiac insufficiency (heart failure), be the variation that initial myocardial damage (as myocardial infarction, cardiomyopathy, hemodynamic overload, inflammation etc.) due to any reason causes myocardial structural and function, finally cause the low of ventricular pump blood and/or full function.Clinical pathogenesis and clinical manifestation are the symptoms such as the dyspnea that causes of myocardial remodelling, unable and fluid retention.Epidemiological study demonstration, 6 years case fatality rate male of patients with heart failure are up to 80%, and women is up to 65%; Serious heart failure year, case fatality rate was up to 50%-60%, its high prevalence, high mortality, life quality decline, viability and ability to work are lost the great hygienic issues that has become harm humans health and life security, also become the Tough questions that China's health service faces.The conventional therapy of cardiac insufficiency diagnoses and treatment guide heart failure in 2007 comprises associating extensive use angiotensin converting enzyme inhibitor (ACEI)/hypertensinⅡreceptorretarder (ARB) and beta-blocker treatment cardiac insufficiency, though it can effectively improve the sings and symptoms of patients with heart failure, but be totally difficult to stop that Cardiac Function of Patients declines and the sustainable development of disease, five year survival rate is not significantly improved, and have the side effect such as hypotension, renal function injury, hyperpotassemia, and not effective to all patients.Therefore, searching applied range, the little medicines of side effect are so the emphasis that medical field is paid close attention to.
Among the mechanism of heart failure and many medicine therapies are being studied, wherein pathogenesis relates to Ventricular Remodeling, the imbalance of matrix metalloproteinase (MMPs) system balancing, the activation of renin angiotensin aldosterone system (RAAS), number of ways such as the activation of sympathetic nervous system, cytokine, apoptosis of cardiac muscle signal transduction pathways.To transferring strategy long-term, reparation property to from short-term hemodynamics/pharmacology measure in its treatment, the neuroendocrine inhibitor of take becomes the Therapeutic Principle of current treatment and prevention cardiac insufficiency as basic treatment.The use in conjunction of ARB, ACEI, diuretic, beta-blockers, cardiac tonic etc. in theory or animal, cell experiment show the effect of certain prevention and treatment heart failure, the test of large-scale prison bed is still in process.
Summary of the invention
The traditional Chinese medical science thinks, the pathogenic characteristic of cardiac insufficiency is deficiency in origin and excess in superficiality, simulataneous insufficiency and excessive; The void of the heart, kidney and negative and positive of qi and blood of take is this, and blood stasis, poison accumulate, diseases caused by retention of fluid is mark.Focus on the Chinese medicine compound integrally-regulated, side effect is little has its original characteristic and advantage in the treatment of cardiac insufficiency, and its multicomponent, effect feature multi-level, too many levels reduce the generation probability of untoward reaction greatly.The invention provides a kind of new Chinese medicines compositions that cardiac function does not conform to that is used for the treatment of, by the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Aconiti Lateralis Preparata, Radix Scrophulariae, Flos Lonicerae, six kinds of Chinese medicines of Radix Glycyrrhizae, according to rational compatibility relationship, formed, according to effective site component, carry out strict Quality Control, select the work sesame of more economic and easy separation and purification active princlple, and reduce cost prepared by active princlple, improve the purity of active component; Total prescription plays the effect of QI invigorating warming YANG, promoting blood circulation and detoxication, and treating both the principal and the secondary aspects of a disease at the same time, usings again benefiting QI for activating blood circulation as the crucial rule for the treatment of.
The Traditional Chinese medicine composition for the treatment of cardiac insufficiency provided by the invention, by the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Aconiti Lateralis Preparata, Radix Scrophulariae, Flos Lonicerae, Radix Glycyrrhizae, formed, each components by weight is the Radix Astragali 10～30: Radix Salviae Miltiorrhizae 10～20: Radix Aconiti Lateralis Preparata 5～15: Radix Scrophulariae 10～15: Flos Lonicerae 10～20, Radix Glycyrrhizae 5～15.Medicine weighs, and carries out proportioning after the extraction of each Effective Component of Chinese Medicine in prescription, in conjunction with the character of active component, six kinds of prescription drugs is carried out to preparation process screening, and system respectively becomes the granule of 8 grams every bag.
This compositions confirms that in previous experiments heart failure after cardiac insufficiency especially experimental myocardial infarction is had to significant curative effect.Its main effect link may be pre-a plurality of links in cardiac insufficiency pathogenesis, as improve myocardium interstitial collagen remodeling, improve myocardial metabolism (increase coronary flow), improve hemorheology, reduce RAAS active and reduce TNF-a expression, remove oxygen-derived free radicals, to reduce the mechanism such as apoptosis of cardiac muscle relevant.
The specific embodiment
Embodiment 1:
Radix Aconiti Lateralis Preparata 9g Radix Astragali 30g Radix Salviae Miltiorrhizae 15g Flos Lonicerae 10g Radix Scrophulariae 10g Radix Glycyrrhizae 6g
Embodiment 2:
Radix Aconiti Lateralis Preparata 9g Radix Astragali 10g Radix Salviae Miltiorrhizae 15g Flos Lonicerae 10g Radix Scrophulariae 10g Radix Glycyrrhizae 10g
Embodiment 3:
Radix Aconiti Lateralis Preparata 6g Radix Astragali 20g Radix Salviae Miltiorrhizae 10g Flos Lonicerae 15g Radix Scrophulariae 15g Radix Glycyrrhizae 10g
Medicine weighs, and carries out respectively proportioning after the extraction of each Chinese medicine active component in prescription, and the active component Radix Astragali total saponins constituents as the Radix Astragali (system), comprises astragaloside I, V, III etc.; The active component alkaloid compound of Radix Aconiti Lateralis Preparata (system), contains aconitine, mesaconitine, hypaconitine etc.; The active component saponins compound of Radix Glycyrrhizae, contains glycyrrhizic acid, enoxolone, 4',7-Dihydroxyflavanone and Angelica Polysaccharide etc.; The active component phenolic acid compound of Radix Salviae Miltiorrhizae, contains salvianolic acid, former a little tea aldehyde, former several boheic acids etc.; The active component cyclenes ether note compounds of Radix Scrophulariae, contains handkerchief Russia glycosides etc.; The active component organic acid compound of Flos Lonicerae, contains chlorogenic acid etc., carries out the compatibility of Chinese medicine active component after extraction according to former prescription amount, is prepared into the granule of 8 grams every bag, every day twice, each two bags.
Experimental technique: rat adaptability was fed after 3 days, and ramus descendens anterior arteriae coronariae sinistrae ligation method is prepared cardiac dsyfunctional rat model, selects electrocardiogram lead to occur 4-6 Q ripple after 3 days, the rat of cardiac function EF value below 50% used rat for testing.This tcm components of experimental therapy group gavage every day, matched group gavage captopril, be clinical equivalent dosage, model group gavage normal saline.Electrocardiogram and ultrasound observation are carried out in administration after 4 weeks, and draw materials and detect the local T NF-α of cardiac muscular tissue, IL-6, AngII, Ald etc.The Optical Morphology of myocardial tissue is observed in the muscular tissue HE that cores dyeing.The capable myocardial collagen volume density of MassonShi three-color process mark is measured.
Experimental result
Result of study shows, compare with model group, treatment group electrocardiogram ∑ abnormality Q wave amplitude, the ST section number significantly decline (P < 0.05) that extremely leads, LVEDd and LVEDs significantly decline (P < 0.05), and EF and FS significantly increase (P < 0.05); The swimming power time that exhausts significantly raises (P < 0.05), stress time respiratory frequency significantly reduce (P < 0.05); Ischemia marginal zone cardiac muscle TNF-α, IL-6, AngII, Ald all significantly reduce; Collagen volume index significantly reduces (P < 0.05).The HE demonstration of dyeing, treatment group myocardium cell injuring degree declines to some extent compared with model group, and inflammatory cell is invaded profit and is alleviated to some extent, and the variation of These parameters is compared with Western medicine group, and swimming power exhausts the time, collagen volume index is better than Western medicine group, but no difference of science of statistics.
Claims (3)
1. a Traditional Chinese medicine composition that is used for the treatment of cardiac insufficiency, it is characterized in that, described compositions is configured to the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Aconiti Lateralis Preparata, Radix Scrophulariae, Flos Lonicerae, Radix Glycyrrhizae, and its weight ratio is the Radix Astragali 10～30, Radix Salviae Miltiorrhizae 10～20, Radix Aconiti Lateralis Preparata 5～15, Radix Scrophulariae 10～15, Flos Lonicerae 10～20, Radix Glycyrrhizae 5～15.
2. pharmaceutical composition as claimed in claim 1, is characterized in that, each Chinese medicine active component in prescription is extracted, and carries out the compatibility of Chinese medicine active component after extraction according to former prescription amount, is prepared into granule and uses.
3. the application of pharmaceutical composition as claimed in claim 1 or 2 in preparation treatment cardiac insufficiency medicine.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410195657.8A CN103989810B (en) | 2010-05-27 | 2010-05-27 | A kind of tcm components that heart function of coronary heart disease is incomplete and preparation method thereof that is used for the treatment of |
| CN201010184304.XA CN102258623B (en) | 2010-05-27 | 2010-05-27 | Chinese medicine composition for treating coronary disease and cardiac insufficiency and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010184304.XA CN102258623B (en) | 2010-05-27 | 2010-05-27 | Chinese medicine composition for treating coronary disease and cardiac insufficiency and preparation method thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410195657.8A Division CN103989810B (en) | 2010-05-27 | 2010-05-27 | A kind of tcm components that heart function of coronary heart disease is incomplete and preparation method thereof that is used for the treatment of |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102258623A CN102258623A (en) | 2011-11-30 |
| CN102258623B true CN102258623B (en) | 2014-05-07 |
Family
ID=45005589
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010184304.XA Active CN102258623B (en) | 2010-05-27 | 2010-05-27 | Chinese medicine composition for treating coronary disease and cardiac insufficiency and preparation method thereof |
| CN201410195657.8A Active CN103989810B (en) | 2010-05-27 | 2010-05-27 | A kind of tcm components that heart function of coronary heart disease is incomplete and preparation method thereof that is used for the treatment of |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410195657.8A Active CN103989810B (en) | 2010-05-27 | 2010-05-27 | A kind of tcm components that heart function of coronary heart disease is incomplete and preparation method thereof that is used for the treatment of |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN102258623B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813728B (en) * | 2012-07-28 | 2014-07-09 | 张茂根 | Traditional Chinese medicine for treating heart-kidney yang deficiency-type chronic heart failure |
| CN107812059B (en) * | 2016-09-14 | 2021-07-02 | 王伟 | Application of traditional Chinese medicine composition |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085435A (en) * | 1992-10-12 | 1994-04-20 | 孙万才 | The manufacture method of vasculitis electuary |
| CN1096445A (en) * | 1993-05-18 | 1994-12-21 | 李文升 | Chinese medicine Zhixindan and manufacture method |
| CN1060665C (en) * | 1996-05-10 | 2001-01-17 | 潘兴光 | Medicine for heart disease |
| CN1957967A (en) * | 2006-11-16 | 2007-05-09 | 沈祥春 | Application of pseudostellaria root for preparing medication of treating cardiovascular disease |
| CN102048895B (en) * | 2011-01-17 | 2012-08-22 | 王仁平 | Pure traditional Chinese medicine preparation for treating dilated cardiomyopathy |
-
2010
- 2010-05-27 CN CN201010184304.XA patent/CN102258623B/en active Active
- 2010-05-27 CN CN201410195657.8A patent/CN103989810B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103989810A (en) | 2014-08-20 |
| CN102258623A (en) | 2011-11-30 |
| CN103989810B (en) | 2016-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258623B (en) | Chinese medicine composition for treating coronary disease and cardiac insufficiency and preparation method thereof | |
| CN102657711B (en) | Cerebral apoplexy treatment medicament and preparation method thereof | |
| CN102727779A (en) | Pharmaceutical composition for treating ovarian cysts and preparation method thereof | |
| CN102335366B (en) | Oral liquor for treating psoriasis and preparation method thereof | |
| CN103479887A (en) | Traditional Chinese medicine formula for treating climacteric dysfunctional uterine bleeding | |
| CN103070943A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine | |
| CN101757544A (en) | Traditional Chinese medicine composition for treating hepatic fibrosis after hepatitis treatment | |
| CN103816445A (en) | Traditional Chinese medicine composition for treating gallstone and preparation method thereof | |
| CN103341057A (en) | Chinese patent medicine pill for treating calculus, nephritis and cholecystitis | |
| CN102274452A (en) | Traditional Chinese medicine for treating gall-stone | |
| CN106421474A (en) | Formula for traditional Chinese medicines capable of lowering blood lipid | |
| CN105343518A (en) | Traditional Chinese medicine formula for treating chronic aplastic anemia and preparation method thereof | |
| CN102940766B (en) | Traditional Chinese medicine for treating chronic nephritis | |
| CN101284117A (en) | Stone dissolution effective prescription | |
| CN105687619A (en) | Traditional Chinese medicine for treating coronary heart disease | |
| CN103110693B (en) | Composition capable of being used for prevention, treatment or auxiliary treatment of cardiovascular and cerebrovascular diseases or chronic diseases as well as preparation method and application thereof | |
| Li et al. | Efficacy and Safety of Yangyin Shuxin Decoction—a Chinese Herbal Medicine Formula For Heart Failure with Preserved Ejection Fraction: A Randomized Controlled Trial | |
| CN103341120A (en) | Purely Chinese herbal preparation for reducing blood pressure | |
| CN104510927A (en) | Traditional Chinese medicine formula for treating hypertension | |
| CN102366505A (en) | Plaster for treating hypertension and preparation method thereof | |
| CN107213333A (en) | Treat the Chinese medicine composition of myocardial fibrosis | |
| Hao et al. | Research Progress of Traditional Chinese Medicine in the Treatment of Hypertension | |
| CN103127348A (en) | Drug for curing female infertility caused by poor ovulation | |
| CN103006996B (en) | Medicine for treating accelerated hypertension | |
| CN101313955B (en) | Anti-dermatophyte compound preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: GUO SHUZHEN Effective date: 20140328 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20140328 Address after: 100029 Beijing, North Third Ring Road, No. 11 East Road, Chaoyang District Applicant after: Wang Wei Address before: 100029 Beijing, North Third Ring Road, No. 11 East Road, Chaoyang District Applicant before: Wang Wei Applicant before: Guo Shuzhen |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Wei Inventor after: Guo Shuzhen Inventor after: Zhang Peng Inventor after: Ni Jian Inventor after: Fu Bangze Inventor before: Wang Wei Inventor before: Guo Shuzhen Inventor before: Zhang Peng Inventor before: Ni Jian |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220110 Address after: 100020 No.11, North Third Ring Road East, Chaoyang District, Beijing Patentee after: BEIJING University OF CHINESE MEDICINE Address before: 100029, No. 11 East Third Ring Road, Chaoyang District, Beijing Patentee before: Wang Wei |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20240430 Address after: No.16 Tongji North Road, Beijing Economic and Technological Development Zone, Daxing District, Beijing, 100176 Patentee after: BEIJING TONG REN TANG TECHNOLOGIES CO.,LTD. Country or region after: China Patentee after: BEIJING University OF CHINESE MEDICINE Address before: 100020 No.11, North Third Ring Road East, Chaoyang District, Beijing Patentee before: BEIJING University OF CHINESE MEDICINE Country or region before: China |